Sen. Ron Wyden Sells Off Shares of Solventum Co. (NYSE:SOLV)

Senator Ron Wyden (D-Oregon) recently sold shares of Solventum Co. (NYSE:SOLV). In a filing disclosed on February 21st, the Senator disclosed that they had sold between $1,001 and $15,000 in Solventum stock on February 6th.

Senator Ron Wyden also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 2/10/2025.
• Sold $1,001 – $15,000 in shares of iRobot (NASDAQ:IRBT) on 2/6/2025.
• Purchased $50,001 – $100,000 in shares of Eli Lilly and Company (NYSE:LLY) on 1/22/2025.

Solventum Stock Down 1.9 %

Shares of NYSE:SOLV opened at $73.08 on Monday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock’s 50-day moving average is $71.14 and its 200-day moving average is $69.24.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Solventum during the 4th quarter worth about $203,740,000. Hotchkis & Wiley Capital Management LLC acquired a new position in Solventum in the third quarter worth about $125,488,000. Trian Fund Management L.P. lifted its stake in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the period. Boston Partners acquired a new stake in Solventum during the fourth quarter valued at approximately $110,378,000. Finally, Independent Franchise Partners LLP grew its stake in shares of Solventum by 105.0% in the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company’s stock valued at $105,904,000 after purchasing an additional 821,272 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have issued reports on SOLV shares. Morgan Stanley raised their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Piper Sandler boosted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $68.29.

About Senator Wyden

Ron Wyden (Democratic Party) is a member of the U.S. Senate from Oregon. He assumed office on January 30, 1996. His current term ends on January 3, 2029. Wyden (Democratic Party, Independent Party) ran for re-election to the U.S. Senate to represent Oregon. He won in the general election on November 8, 2022. He advanced from the Democratic primary on May 17, 2022. In 2018, the Town Hall Project, which described itself as “a citizen powered, grassroots effort that empowers constituents across the country to have face-to-face conversations with their elected representatives,” named Wyden town hall MVP for the second year in a row. According to OregonLive, Wyden held over 900 town hall meetings between 1996 and 2018. Wyden previously served in the U.S. House of Representatives, representing Oregon’s 3rd Congressional District from 1981 to 1996. As of a 2014 analysis of multiple outside rankings, Wyden is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.